Kornimate/medical-research-clean huggingface dataset:
effects of lateral trunk support on spinal alignment in spinal cord injured persons

Conditions: Scoliosis; Spinal Cord Injury

Summary: the effects of lateral trunk supports (lts) in special seating on the spinal alignment of 17 spinal cord injured (sci) subjects with scoliosis were studied using bi-planar radiographs. the lts improved significantly the functional scoliotic spinal alignment in the frontal and sagittal planes regardless of the severity of scoliosis.

sci patients often develop progressive scoliosis due to loss of muscular support to maintain good sitting posture. special seating with lts has been widely used in clinical practice to improve their sitting postures. however, little is known as to how this can affect the scoliotic curve.the purpose of this study was to investigate the effects of lateral trunk supports (lts) in special seating on the spinal alignment of spinal cord injured (sci) individuals with scoliosis. ten male and seven female sci subjects with scoliosis sat on an experimental chair with and without lts while radiographs of the spine in the anteroposterior and lateral directions were taken. radiographs of the spine in the a-p and lateral directions were taken with a digital radiographic imaging system (saturn 9000 m, comed., korea). for each direction, the complete image of the spine was obtained from separate x-ray images of the upper and lower trunk due to the limited field of view of the x-ray machine. the cobb angles and scoliotic indices based on the anteroposterior radiographic images and the angles of the thoracic and lumber spine based on lateral were calculated.

Eligibility criteria:
inclusion criteria: * (1) c4-t12 sci, (2) onset over 1 year, (3) sitting on the wheelchair more than 4 hours per day, (4) diagnosed thoracic or lumbar scoliosis through a-p radiographs, (5) flexible scoliosis, confirmed by supine and side-lying bending radiographs. exclusion criteria: * inflexible scoliosis

Keywords: scoliosis spinal cord injury lateral trunk support radiography
tdcs and robotic therapy in stroke

Conditions: Stroke; Upper Extremity Impairments

Summary: after stroke a limited motor recovery in the paretic upper limb accounts for a large proportion of the disabling sequelae. only about 15% of those with initial complete upper limb paralysis after stroke recover functional use of their impaired arm in daily life. the aim of this study is to test the effects of tdcs combined with upper extremity robot-assisted therapy on stroke survivors.


Eligibility criteria:
inclusion criteria: * males and females subjects. age \> 18 years. * diagnosis of first ischemic stroke * impairment of the upper limb * trunk control defined in the trunk-control test (tct), with a score \> 50. exclusion criteria: * anyone who does not have adequate understanding of verbal or written information in italian sufficient to complete any test * impaired cognitive functioning: score less than 24 on the mini mental status examination (mmse) * contraindications to single-pulse transcranial magnetic stimulation (tms)(tms will be used to measure cortical excitability): presence of a history of epilepsy, frequent headaches or neck pain, implantable devices (ventriculoperitoneal shunts, pacemakers, intrathecal pumps, intracranial metal implants) * contraindications to tdcs: intracranial metal implants that can be stimulated, incorrectly positioned or over-heated by the electric current * neurological or psychiatric pathology * severe cardio-pulmonary, renal, hepatic diseases * pregnancy
radiotherapy vs observation for crpc

Conditions: Hormone Refractory Prostate Cancer

Summary: the purpose of the study is to determine whether radiotherapy improves cancer control and overall survival among patients with castration resistant prostate cancer.


Eligibility criteria:
inclusion criteria: 1. eligible patients had histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiologic evidence of disease progression during hormonal therapy 2. patients were receiving primary androgen-ablation therapy as maintenance therapy. at least four weeks had to have elapsed between the withdrawal of antiandrogens (six weeks in the case of bicalutamide) and enroll ment, so as to avoid the possibility of confounding as a result of the response to antiandrogen withdrawal. 3. another requirement was disease progression, as indicated by increasing serum levels of psa on three consecutive measurements obtained at least one week apart or findings on physical examination or imaging studies. 4. normal cardiac function was required. exclusion criteria: 1. patients had a karnofsky performance-status score of at most 60 percent 2. prior treatment with cytotoxic agents or radioisotopes 3. with history of another cancer within the preceding five years, brain or leptomeningeal metastases, symptomatic peripheral neuropathy of grade 2 or higher, and other serious medical condition.

Keywords: adenocarcinoma prostatic neoplasms carcinoma prostatic diseases
efficacy and safety of bendamustine plus rituximab in chronic lympocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: this study is intended for chronic lymphocytic leukemia patients who have already undergone a first or second treatment with drugs named bendamustine and rituximab. it will observe the results of this treatment and evaluate its efficacy and side effects.

this cohort study will recruit chronic lymphocytic leukemia (cll) patients who were treated with first and second-line bendamustine plus rituximab (br) from january 2008 to december 2014 from european centres adhering to the gimema group and the eric group, and aims at observing the progression-free survival in cll patients.

Eligibility criteria:
inclusion criteria: * diagnosis of cll / small lymphocytic lymphoma (cll/) according to the world health organisation (who) classification 2008. * patients who were treated with first and second-line bendamustine plus rituximab (br) from january 2008 to december 2014 from european centres adhering to the gimema group and the eric group. * previously untreated cll patients requiring therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of br as first-line treatment. * cll patients that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the nci criteria (hallek m et al, blood 2008 - appendix g) and treated with at least one cycle of bendamustine and rituximab. * age ≥ 18 years old. * signed written informed consent according to ich/eu/gcp and national local law. exclusion criteria: * patients who have received 2 or more lines of prior therapy. * patients with: transformation of cll into aggressive lymphomas (richter's syndrome). hiv infection. active and uncontrolled hcv and/or hbv infections or liver cirrhosis.
nosocomial infections during total prostatic cystectomies (tpc) with replacement enterocystoplasty: prophylactic role of urell®, cranberry fruit juice extract (vaccicium macrocarpon)

Conditions: Bladder Cancer

Summary: total prostatic cystectomy with enterocystoplasty is the most extensive urological surgical procedure and one with the highest complication rate, especially infectious complication. the mortality rate remains substantial (2 to 5%). examination of hundreds of tpcs made every year in the urology department of foch hospital, shows that nosocomial urinary infection is constant, especially when the tpc is followed by the constitution of an ileal bladder replacement. this is due to the intervention itself and duration of postoperative urinary cathéters (ureteral and bladder). this leads to increase surveillance and antibiotic treatment, given the risks of declared infection in this context. detailed analysis of the last 20 tpcs with enterocystoplasty showed the presence of germs in significant numbers, in all cases. urell® (also sold under the trademark ellura®) contains a cranberry juice extract with a high content of bioactive, soluble proanthocyanidins (pacs) . the daily dose is 36 mg total pacs measured by the dmac/a2 method. the pacs prevent uropathogenic e.col bacteria from adhering to uroepithelial cells . their long term use does not create any resistance of the bacteria. the excellent prophylactic effet of urell® had been previously observed in the same center under different conditions. therefore a further demonstration was justified, of the prophylactic efficacy of urell® in the perioperative setting of total prostato-cystectomy with substitute enterocytoplasty, where the slightest urinary infection, symptomatic or not, prolongs hospitalization and requires antibiotic treatment because of its harmful and sometimes major consequences.


Eligibility criteria:
inclusion criteria: * patient aged \> 18 years old * patient with bladder cancer and total prostatic cystectomy with replacement enterocystoplasty * signed informed consent * patient with healthcare insurance exclusion criteria: * patient without signed informed consent * patient deprived of liberty by judicial or administrative decision
dose escalation study with zactima and chemotherapy in metastatic pancreas carcinoma

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to define th maximum tolerated dose (mtd) and the recommended dose (rd) of zd6474 in combination with a fixed standard dose of gemcitabine and capecitabine


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of locally advanced unresectable or metastatic pancreatic adenocarcinoma * ecog performance status \<1 * measurable disease exclusion criteria: * severe or uncontrolled systemic disease * clinically significant cardiac event such as myocardial infarction * any concomitant medication that may cause otc prolongation, include torsades de pointes

Keywords: pancreatic cancer pancreatic adenocarcinoma pancreas cancer dose escalation study locally advanced unresectable pancreatic adenocarcinoma zactima vandetanib zd6474
fractional co2 laser followed by either vitamin c or tranexamic acid in treatment of melasma.

Conditions: Melasma

Summary: the aim of the study: 1.to compare the efficacy and safety of fractional co2 laser in combination with vitamin c and tranexamic acid in the treatment of melasma. 2 .to assess the value of dermoscope in measuring of the response to treatment in melasma patients compared to clinical scoring.

melasma is a chronic dermatologic condition defined by hyperpigmented macules and patches that appear in areas of sun exposure . traditionally, the mainstays of treatment for melasma have been topical bleaching agents and strict photoprotection. additional adjuvant treatment modalities include chemical peels, dermabrasion, and laser treatments, all of which have demonstrated limited efficacy. there has been an interest in studying the effects of vitamin c and tranexamic acid in melasma. the development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction. these microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes.

Eligibility criteria:
inclusion criteria: 1. all types of melasma (epidermal, dermal, and mixed) will be included . 2. patients older than 19 years of age. exclusion criteria: 1. pregnancy, breastfeeding. 2. patients taking drugs that induce facial pigmentation e.g, oral contraceptive pills, or hormonal replacement therapy at the time of the study or during the past 12 months. 3. patients using of any topical bleaching within 1 month before recruitment. 4. employment of chemical peels or laser therapy during the past 6 months. 5. concomitant use of anticoagulants, bleeding disorders.
study of visual-spatial attention by eye tracking as a function of central or peripheral visual impairment

Conditions: Central or Peripheral Visual Impairment

Summary: the objective of this pilot work is to determine the role of central and peripheral visions in explicit attention processes (saccade planning) in the case of visual impairment.


Eligibility criteria:
inclusion criteria: * male or female ≥18 years; * patient with a central visual deficit (central scotoma on the visual field: dmla, cones dystrophy ...) or peripheral (annular scotoma: chronic glaucoma, retinitis pigmentosa ...) or without visual deficit (corrected visual acuity and visual field) * patient agreeing to participate in the study and signing informed consent * patient affiliated to social security exclusion criteria: * pregnant woman * patient with known epilepsy * major under judicial safeguard, or deprived of liberty * major under guardianship or curatorship or admitted to a health or social institution for purposes other than research.
study of ifn-k in dermatomyositis

Conditions: Dermatomyositis

Summary: this study is a proof of concept study aiming to evaluate the production of anti-ifnα antibodies (immune response) in adult subjects with dermatomyositis


Eligibility criteria:
inclusion criteria: * patient newly diagnosed or relapsing with "definite" or "probable" dermatomyositis based on enmc criteria (2004) * patient requiring corticosteroids (cs) at a dose of 1 mg/kg and ≤ 70 mg of prednisone equivalent/day or currently receiving cs at a dose of 1 mg/kg and ≤ 70 mg of prednisone equivalent/day * is a male or female, aged between 18 and 65 years, inclusive, at the time of the screening visit * study patient and his/her partner of child bearing potential has to use effective method of contraception exclusion criteria: * is high-risk human papilloma virus (hpv) positive by (rt-pcr) on a cervical swab * has cytological abnormalities ≥ hsil on a cervical swab * is positive for autoantibodies anti-nxp2, tif1ɤ, mda5 associated with severe pulmonary disease or anti-synthetase antibodies * is positive for any malignancy or has a history of any malignancy * has received iv pulse dose cs (≥ 250 mg prednisone equivalent/day) * has received intravenous immunoglobulin (ivig) * has received potent immunosuppressive drugs such as cyclophosphamide, methotrexate, azathioprine, mycophenolate, cyclosporine a, oral tacrolimus * has received abatacept, anifrolumab, belimumab, tnf antagonists or another registered or investigational biological therapy * has received anti-b-cell therapy (e.g. rituximab, epratuzumab) * has received any live vaccine * has used any investigational or non-registered product , or any investigational or non-registered vaccine * has inflammatory joint or skin disease other than dermatomyositis that may interfere with study assessments * has frequent recurrences of oral or genital herpes simplex lesions * is at high risk of significant infection and/or has any current signs or symptoms of infection at entry or has received intravenous antibiotics
effects of variable ventilation on respiratory system of acute respiratory distress syndrome (ards) patients

Conditions: ARDS

Summary: the purpose of this study is to determine the effects of variable ventilation on respiratory system of patients affected by acute respiratory distress syndrome.

in this interventional study we want to evaluate the effect of variable ventilation (1) in patients with ards. patients will be mechanically ventilated with variable ventilation (3 step with increased level of variability) and "traditional" cmv, for a total of 4 step. each step lasts in 60 minutes. during this period we will record the gas exchange parameters and the mechanics of the respiratory system. 1. arold s, mora r, lutchen k, et al. variable ventilation improves lung mechanics and gas exchange in a rodent model of acute lung injury. am j resp crit care med 2000; 165: 366-71.

Eligibility criteria:
inclusion criteria: * patients with ards criteria exclusion criteria: * age less than 18 years * severe haemodynamic instability * patients with clinical or instrumental evidence of flow-limitation (i.e., peepi)

Keywords: ards mechanical ventilation variable ventilation chaotic ventilation
a pilot study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of abt-450 with ritonavir (abt-450/r) dosed in combination with abt-072 and ribavirin (rbv)

Conditions: Hepatitis C; HCV; Chronic Hepatitis C Infection; Hepatitis C Genotype 1

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of abt-450 with ritonavir (abt-450/r) dosed in combination with abt-072 and ribavirin (rbv) in treatment-naïve participants with genotype 1 chronic hepatitis c virus (hcv) infection.

this was a phase 2a multicenter, open-label, single arm, combination treatment study of a regimen of abt-450/r/abt-072, and ribavirin (rbv) in hepatitis c virus (hcv) genotype 1-(1a or 1b) infected treatment-naïve participants.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c, genotype 1 infection with interleukin 28b (il28b) rs12979860 genotype c/c. * liver biopsy within 3 years with histology consistent with hepatitis c virus (hcv) - induced liver damage, with no evidence of cirrhosis or liver pathology due to any cause other than chronic hcv. * treatment naïve male or female between the ages of 18 and 65. * females must be postmenopausal for at least 2 years or surgically sterile. * be in a condition of general good health, as perceived by the investigator, other than hepatitis c virus infection. * body mass index 18 to \< 35 kg/m\^2 . exclusion criteria: * significant sensitivity to any drug. * use of herbal supplements within 2 weeks prior to study drug dosing. * positive screen for certain drugs or alcohol. * positive hepatitis b surface antigen or anti-human immunodeficiency virus (hiv) antibody. * use of strong cytochrome p450 3a (cyp3a), cytochrome p450 2c8 (cyp2c8), and organic anion transporting polypeptide 1b1 (oatp1b1) enzyme inducers or inhibitors within 1 month of dosing. * prior treatment with any investigational or commercially available anti-hepatitis c virus agents. * abnormal laboratory tests. * cirrhosis or extensive bridging fibrosis. * history of cardiac disease.
ngal, an early predictive marker of acute kidney injury after cardiac surgery in neonates and infants

Conditions: Peritoneal Lesion

Summary: urinary ngal has been shown to be an early marker of acute kidney injury (aki) following paediatric cardiac surgery (2 hours off pump). previous studies showed that an early increase of urinary ngal following cardiopulmonary bypass was predictive of aki. several studies included heterogeneous populations of children undergoing cardiac surgery, but ngal has not been studied in neonates after open heart surgery, neither has been identified the threshold for accurate prediction of severe aki requiring renal replacement therapy. the aim of this observational cohort study is to describe postoperative kinetics of urinary ngal in neonates and to identify the threshold for accurate prediction of severe aki requiring renal replacement therapy in neonates and infants undergoing cardiac surgery

urinary ngal has been shown to be an early marker of aki following paediatric cardiac surgery (2 hours off pump). previous studies showed that an early increase of urinary ngal following cardiopulmonary bypass was an excellent predictor for a later \>50% increase in serum creatinine concentration in children undergoing cardiac surgery. increased urinary concentrations of ngal were found following open heart surgery. when defining aki as an \>50% increase of serum creatinine from baseline, the increase of urinary ngal concentration two hours off pump appeared to be an excellent predictor of aki. several studies included heterogeneous populations of patients aged one month to 21 years undergoing cardiac surgery. besides, ngal concentrations have not been studied in neonates after open heart surgery, neither has been identified the threshold for accurate prediction of severe aki requiring renal replacement therapy (rrt). if such a threshold was identified, urinary ngal could be provided for intervention. the aim of this observational cohort study is to describe postoperative kinetics of urinary ngal in neonates and to identify the threshold for accurate prediction of severe aki requiring rrt in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass. the study is entirely observational, the decision to initiate rrt continues to be based on clinical evidence of fluid overload, low cardiac output and oliguria. urine samples are collected during the early postoperative period, stored, than ngal concentrations are measures on the architect platform.

Eligibility criteria:
inclusion criteria : * term neonates and infants undergoing heart surgery with cardiopulmonary bypass * parents received written information exclusion criteria : * preoperative documented kidney injury * parents not informed, opposed

Keywords: postoperative complications acute kidney failure peritoneal dialysis ngal
comparative evaluation of puspens and c&cs

Conditions: Opioid-Related Disorders

Summary: this observational study compares the health and social outcomes between opioid-dependent individuals who are either recently released from a compulsory drug detention center (cddc) or recently discharged from a voluntary treatment center (vtc) providing methadone maintenance therapy, in malaysia.

in july 2010, the national anti-drug agency of malaysia (nada) introduced a non-punitive system of treatment and care for people who use drugs, voluntary treatment centers (vtcs), called 'cure \& care' clinics, offering free methadone maintenance therapy (mmt) to opioid-dependent drug users. these centers were opened alongside existing compulsory drug detention centers (cddcs), where people who use drugs continue to be detained involuntarily without access to evidence-based treatment. given that both of these programs are operated by nada but espouse vastly different responses to drug use, we compared health and social outcomes between opioid-dependent individuals recently released from cddcs and recently initiated into mmt in the new vtcs.

Eligibility criteria:
inclusion criteria: * meets diagnostic and statistical manual-iv criteria for opioid dependence * physically and psychologically capable of understanding and undergoing informed consent process * within 90 days of release or discharge and intending to return to klang valley region * for vtc arm, came to the c\&c to start mmt

Keywords: malaysia asia southeast asia compulsory drug detention centers compulsory centers for drug users methadone drug relapse drug and narcotic control opiate substitution treatment prisons